Inventor
WU JIAXI
US13 patents
⚠️ This page may combine multiple inventors who share the name “WU JIAXI”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
REGENERON PHARMA
8 patentsUS11725034B2Aug 15, 2023
IL2 agonists and methods of use thereof
REGENERON PHARMA4 citations84
US12091440B2Sep 17, 2024
IL2 and peptide-MHC complex fusion proteins and methods of use thereof
REGENERON PHARMA1 citations71
US12522638B2Jan 13, 2026
IL12 receptor agonists and methods of use thereof
REGENERON PHARMA0 citations61
US12319724B2Jun 3, 2025
IL2 agonists and methods of use thereof
REGENERON PHARMA0 citations61
US12215131B2Feb 4, 2025
IgG Fc-IL2-Rα-IL2 fusions and methods of use thereof
REGENERON PHARMA0 citations61
US12168681B2Dec 17, 2024
Il-2 variants with reduced binding to IL-2 receptor alpha and uses thereof
REGENERON PHARMA0 citations60
US11834485B2Dec 5, 2023
IL-2 variants with reduced binding to IL-2 receptor alpha and uses thereof
REGENERON PHARMA0 citations60
US12528851B2Jan 20, 2026
IL2-based therapeutics and methods of use thereof
REGENERON PHARMA0 citations50
UNIV TEXAS
5 patentsUS10336786B2Jul 2, 2019
Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
UNIV TEXAS4 citations83
US11492368B2Nov 8, 2022
Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
UNIV TEXAS1 citations72
US10633411B2Apr 28, 2020
Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
UNIV TEXAS3 citations72
US10508129B2Dec 17, 2019
Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
UNIV TEXAS3 citations72
US10696710B2Jun 30, 2020
Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
UNIV TEXAS0 citations51